Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-09T05:41:14.416Z Has data issue: false hasContentIssue false

Outcomes in Patients with Untreated Versus Treated Asymptomatic Bacteriuria within 5 Veterans Affairs Facilities

Published online by Cambridge University Press:  16 September 2024

Kelly Davis
Affiliation:
Lexington VA HealthCare System
Jessica Bennett
Affiliation:
Lt. Col Weathers Jr VA Medical Center
Angela Kaucher
Affiliation:
James H. Quillen VA Medical Center
Bowden Jarred
Affiliation:
Lt. Col. Luke Weathers, Jr. VA Medical Center
Brittany DeJarnett
Affiliation:
Robley Rex VA Medical Center
Garrett Fannin
Affiliation:
Lexington VA HealthCare System
Morgan Johnson
Affiliation:
Tennessee Valley Healthcare System
Anna Mitchell
Affiliation:
Department of Veterans Affairs
Colby Osborne
Affiliation:
James H. Quillen VA Medical Center
Caroline Powers
Affiliation:
Ralph H. Johnson VA Medical Center
Caroline Williams
Affiliation:
Lt. Col. Luke Weathers, Jr. VA Medical Center
Dana Williams
Affiliation:
Lt. Col. Luke Weathers, Jr. VA Medical Center
Hans Scheerenberger
Affiliation:
James H. Quillen VA Medical Center

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Asymptomatic bacteriuria (ASB) is often treated with antibiotics despite recommendations against screening for and treating ASB in most populations. Some providers cite concern for progression of ASB to a symptomatic urinary tract infection (UTI) as the jultification for antibiotic use. While the 2019 Infectious Diseases Society of America (IDSA) ASB guidelines refute this concern, most evidence is derived from studies done in females, potentially limiting external validity. The purpose of this study is to compare the outcomes of patients with ASB who received antibiotic treatment versus those who did not in a primarily male population. Methods: This is a multi-center, retrospective, cohort study conducted by the 5 sites within the Veterans Affairs MidSouth Healthcare Network. Patients with a positive urine culture (defined as cultures with a colony forming unit count >100,000) collected from January 1, 2021 through December 31, 2021 were identified. ASB was determined via chart review using pre-determined criteria (positive culture in the absence of reported or documented signs or symptoms attributable to UTI as defined by the 2019 IDSA ASB guidelines). Additional data collected included antibiotic use, clinic visits and hospital admissions related to UTI or sepsis from a UTI. The primary outcome was the comparison of UTI incidence at 30 days, 6 months, and 1 year in those untreated versus treated with antibiotics. Secondary outcomes included a comparison of admissions with sepsis from UTI and adverse drug reactions (ADRs) between the cohorts. Continuous data were analyzed using a Student’s t-test. Discrete data were analyzed using either a Chi-squared or Fisher’s exact test. Results: The study population was primarily elderly (73 years, range 27-99 years) and male (79.7%). Of the 281 patients with ASB, 127 (45.2%) and 154 (54.8%) were untreated and treated, respectively. The incidence of UTI was 3% versus 1% (p = 0.41) at 30 days, 10% versus 12% (p = 0.61) at 6 months and 11% versus 12% (p = 0.94) at 12 months in the untreated and treated cohorts, respectively. There was no difference in admissions for UTI, sepsis from UTI or ADRs at 30 days. Conclusion: This study found no difference in the development of symptomatic UTI in veterans with untreated ASB compared to those treated with antibiotics. These findings align with current ASB guideline recommendations and support avoidance of unnecessary antibiotic use in the veteran population.

Type
Antibiotic Stewardship
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America